Aurinia Pharmaceuticals Initiates Phase 4 PRESERVE Study in Lupus Nephritis Combination Therapy

Neutral

AI Analysis

Summary

Aurinia Pharmaceuticals has initiated a Phase 4 PRESERVE study investigating combination therapy for lupus nephritis. The study represents post-marketing surveillance for an approved indication.

Clinical Trial Data

Phase

Phase 4

Importance:3/10

Sentiment:

0.00

Phase 4Lupus NephritisCombination TherapyClinical Trial

Related Companies

$AUPH

Read the original article

Published by yahoo_finance on July 6, 2026 12:28 PM

Read Original